Although adjuvant hormone therapy was shown to be effective for ER-positive breast cancers [25], and adjuvant trastuzumab therapy was also shown to improve the survival of HER2 positive breast cancers [26,27], TNBCs have no targeted therapy at present. The gene discussed is ERBB2; the disease is breast carcinoma.